Shuvro Roy is a Neurology physician affiliated with University of Washington. OpenAlex indexes 42 publications with 233 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1536 N 115th St Ste 130
Seattle, WA 981338416
Telephone
206-520-5000Provider last certified this registry record 25 Jul 2023.
Clinical trials
- Trial of eHealth Wellness Behavioral Interventions and Patient-reported Outcomes
Sponsor: Johns Hopkins University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202517 payments$14,254openpaymentsdata.cms.gov ↗
- Genentech USA, Inc.Program year20257 payments
- Alexion Pharmaceuticals, Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
35.3%CD20-directed Cytolytic Antibody21.6%Kesimpta Pen100%Part D<11 patientsPyrimidine Synthesis Inhibitor13.8%Teriflunomide100%Part D<11 patientsNervous system
34.5%Potassium Channel Blocker12.1%Dalfampridine Er100%Part D<11 patientsSympathomimetic-like Agent11.2%Modafinil100%Part D<11 patients+ 1 more class in this area
Musculoskeletal
30.2%gamma-Aminobutyric Acid-ergic Agonist30.2%Baclofen100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Neal Futran, MD, DMD
University of Washington
Elizabeth Swisher
University of Washington
David Tirschwell
University of Washington
Elaine Peskind, MD
University of Washington
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”